Infectious Disease Diagnostics Market

Infectious Disease Diagnostics Market by Product (Reagents, Assays, Instrument), Test (Laboratory, POC), Technology (Immunodiagnostics, Microbiology, PCR, NGS, INAAT), Disease (COVID-19, Hepatitis, HAI, HIV, Influenza), End User - Global Forecast to 2026

Report Code: MD 3088 May, 2021, by marketsandmarkets.com

[263 Pages Report] The global infectious disease diagnostics market size is projected to reach USD 39.8 billion by 2026 from USD 28.1 billion in 2021, at a CAGR of 7.2%. Market growth is driven by the global prevalence of infectious diseases & onset of COVID-19 and the growing awareness for early disease diagnosis, shift in focus from centralized laboratories to decentralized POC testing and rising technological advancements.

Infectious Disease Diagnostics Market

COVID-19 Impact on Global Infectious Disease Diagnostics Market

COVID-19 is an infectious disease caused by the most recently discovered novel coronavirus. Largely unknown before the outbreak began in Wuhan (China) in December 2019, COVID-19 moved from a regional crisis to a global pandemic in just a matter of a few weeks. The COVID-19 pandemic negatively affected the overall sales of most of the companies but had an positive impact on the infectious disease diagnostics market because of the use of infectious disease diagnostic methods for COVID-19 testing. Lockdowns resulting from the COVID-19 pandemic caused people to delay undergoing health checkups, thus affecting the number of tests being performed and sales of reagents. However, a resurgence in testing numbers is seen as countries gradually ease restrictions on movement. With the COVID-19 pandemic, responding to infectious disease has become a pressing medical issue worldwide. In addition to the development of vaccines and therapeutic drugs, there is a growing call for the development of more precise and simple testing technologies and the expansion of testing structures. COVID-19 has also impacted the regulatory environment and practices, as governments and healthcare providers face unprecedented challenges. Regulatory authorities utilized methods to speed approval of diagnostic products. Companies have taken strategic developments to introduce COVID-19 rapid tests, sustain their revenues, and nullify the impact of COVID-19 on their operational capabilities

Market Dynamics

Driver: Global prevalence of infectious diseases and onset of COVID-19
The prevalence of infectious diseases in developed and developing regions will positively influence the growth of the infectious disease diagnostics market. The diagnosis and management of such diseases are responsible for the increasing number of prescriptions for infectious disease diagnostic tests. These factors, alongside the growing trend for preventive medicine, is expected to drive the demand for infectious disease diagnostics during the forecast period. The broad-scale population-based testing is required to improve prevention and control efforts for COVID-19. These tests are performed by infectious disease diagnostics; hence, it is expected to have a positive impact on this market.

Opportunity: Growing opportunities in growing economies
Developing economies such as India, South Korea, Brazil, and Mexico are expected to offer potential growth opportunities for major players operating in the infectious disease diagnostics market. This can be attributed to the high disease prevalence, large patient population, improving healthcare infrastructure, increasing disposable income, and growing medical tourism in these countries. In addition to the factors mentioned above, the Asia Pacific has emerged as an adaptive and business-friendly hub due to relatively less stringent regulations and data requirements.
Restraint: Unfavourable reimbursement scenario
Inadequate reimbursement is a major factor restraining the growth of the infectious disease diagnostics market. A major challenge that most diagnostic companies face in commercializing their tests is getting health insurers to pay for them.
“In 2020, reagents, kits, and consumables segment accounted for the largest share of the infectious disease diagnostics market, by product & service”
Based on product & service, the infectious disease diagnostics market is segmented into reagents, kits, and consumables; instruments; and software & services. In 2020, the reagents, kits, and consumables segment accounted for the largest share of this market. The frequent purchase of these products due to their recurrent usage drives the market growth of this segment.
In 2020, immunodiagnostics segment accounted for the largest share in the market, by technology”
The infectious disease diagnostics market is segmented into immunodiagnostics, polymerase chain reaction (PCR), clinical microbiology, isothermal nucleic acid amplification technology (INAAT), DNA sequencing & NGS, DNA microarrays, and other technologies. In 2020, the immunodiagnostics segment accounted for the largest share. This can be attributed to the increasing use of immunoassays in COVID-19 testing, POC infectious disease testing, the development of novel immunodiagnostic tests, and the rising trend of automation.
North America is the largest regional market for the infectious disease diagnostics”
The global infectious disease diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the global infectious disease diagnostics market. The North American infectious disease diagnostics market's growth can be attributed to the highly developed healthcare system in the US and Canada, the presence of many leading national clinical laboratories, and the easy accessibility to technologically advanced instruments.

Infectious Disease Diagnostics Market  by Region

Some key players in the infectious disease diagnostics market (2021- 2026)

  • Abbott Laboratories (US)
  • Roche Diagnostics Ltd. (Switzerland)
  • bioMérieux SA (France)
  • Thermo Fisher Scientific Inc. (US)
  • Danaher Corporation (US)

Scope of the Report

Report Metric

Details

Market size available for years

2019–2026

Base year considered

2020

Forecast period

2021–2026

Forecast units

Value (USD Billion)

Segments covered

Product & Service, type of testing, technology, disease type, end user, and region

Geographies covered

North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Companies covered

Abbott Laboratories (US), F. Hoffmann-La Roche Ltd(Switzerland), bioMérieux SA (France), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Quidel Corporation(US), Hologic, Inc. (US), Siemens Healthineers AG (Germany), Becton, Dickinson and Company (US), PerkinElmer Inc. (US), QIAGEN (Netherlands), Grifols S.A. (Spain), DiaSorin S.p.A (Italy), Bio-Rad Laboratories, Inc. (US), Sysmex Corporation (Japan), Ortho Clinical Diagnostics (US), Luminex Corporation (US), Meridian Bioscience (US), Genetic Signatures (Australia), OraSure Technologies (US), Trinity Biotech Plc. (Ireland), Chembio Diagnostic Systems, Inc. (US), Seegene Inc. (South Korea), Co-Diagnostics, Inc. (US), ELITechGroup (France), Epitope Diagnostics, Inc. (US), Trivitron Healthcare (India), Meril Life Sciences Pvt. Ltd. (India), InBios International, Inc. (US), and ABACUS Diagnostica Oy (Finland).

This report categorizes the infectious disease diagnostics market into the following segments and subsegments:

By Product

  • Reagents, Kits, and Consumables
  • Instruments
  • Software & Services

By Type of Testing

  • Laboratory Testing
  • POC Testing

By Technology

  • Immunodiagnostics
  • Clinical Microbiology
  • PCR
  • INAAT
  • DNA Sequencing & NGS
  • DNA Microarrays
  • Other technologies

By Disease Type

  • COVID-19
  • HIV
  • HAIs
  • Hepatitis
  • CT/NG
  • HPV
  • TB
  • Influenza
  • Other Infectious Diseases

By End User

  • Diagnostic Laboratories
  • Hospitals & Clinics
  • Academic Research Institutes
  • Other End Users

By Region

  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific (RoAPAC)
  • Latin America
  • Middle East & Africa

Recent Developments

  • In March 2021, Roche Diagnostics Launched cobas SARS-CoV-2 Variant Set 1 Test to help monitor emerging coronavirus mutations.
  • In February 2021, Thermo Fisher Scientific acquired Mesa Biotech (US) to expand the benefits of molecular diagnostics at the point of care.
  • In March 2020, Abbott Laboratories launched the ID NOW COVID-19 Test.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 30)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
           1.2.2 MARKETS COVERED
           1.2.3 YEARS CONSIDERED FOR THE STUDY
    1.3 CURRENCY
    1.4 LIMITATIONS
    1.5 STAKEHOLDERS
    1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 34)
    2.1 RESEARCH DATA
    2.2 RESEARCH APPROACH
           FIGURE 1 INFECTIOUS DISEASE DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY
           2.2.1 SECONDARY DATA
                    2.2.1.1 Key data from secondary sources
           2.2.2 PRIMARY DATA
                    2.2.2.1 Key data from primary sources
                    2.2.2.2 Key industry insights
                               FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.3 MARKET SIZE ESTIMATION
           2.3.1 BOTTOM-UP APPROACH
                    FIGURE 3 INFECTIOUS DISEASE DIAGNOSTICS MARKET: BOTTOM-UP APPROACH
                    FIGURE 4 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
           2.3.2 TOP-DOWN APPROACH
                    FIGURE 5 INFECTIOUS DISEASE DIAGNOSTICS MARKET: TOP-DOWN APPROACH
    2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
           FIGURE 6 DATA TRIANGULATION METHODOLOGY
    2.5 ASSUMPTIONS FOR THE STUDY
    2.6 RISK ASSESSMENT
           TABLE 1 RISK ASSESSMENT: INFECTIOUS DISEASE DIAGNOSTICS MARKET
    2.7 COVID-19 HEALTH ASSESSMENT
    2.8 COVID-19 ECONOMIC ASSESSMENT
    2.9 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
           FIGURE 7 CRITERIA IMPACTING THE GLOBAL ECONOMY
           FIGURE 8 RECOVERY SCENARIO OF THE GLOBAL ECONOMY
    2.10 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO IN THE INFECTIOUS DISEASE DIAGNOSTICS MARKET

3 EXECUTIVE SUMMARY (Page No. - 47)
    FIGURE 9 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021 VS. 2026 (USD MILLION)
    FIGURE 10 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
    FIGURE 11 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021 VS. 2026 (USD MILLION)
    FIGURE 12 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
    FIGURE 13 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2021 VS. 2026 (USD MILLION)

4 PREMIUM INSIGHTS (Page No. - 51)
    4.1 INFECTIOUS DISEASE DIAGNOSTICS MARKET OVERVIEW
           FIGURE 14 THE RISING ADOPTION OF POC DIAGNOSTICS IS EXPECTED TO SUPPORT MARKET GROWTH DURING THE FORECAST PERIOD
    4.2 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021 VS. 2026 (USD MILLION)
           FIGURE 15 REAGENTS, KITS, AND CONSUMABLES SEGMENT TO COMMAND THE LARGEST SHARE OF THE MARKET, BY PRODUCT & SERVICE, IN 2021
    4.3 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
           FIGURE 16 IMMUNODIAGNOSTICS TO HOLD THE LARGEST SHARE OF THE MARKET DURING THE FORECAST PERIOD
    4.4 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021 VS. 2026
           FIGURE 17 DIAGNOSTIC LABORATORIES DOMINATE THE END-USER MARKET

5 MARKET OVERVIEW (Page No. - 54)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           FIGURE 18 INFECTIOUS DISEASE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Global prevalence of infectious diseases and onset of COVID-19
                    5.2.1.2 Rising focus on R&D and funding in infectious disease diagnostics
                    5.2.1.3 Growing awareness for early disease diagnosis in developing countries
                    5.2.1.4 Rising technological advancements in infectious disease diagnostics
                    5.2.1.5 Shift in focus from centralized laboratories to decentralized POC testing
           5.2.2 RESTRAINTS
                    5.2.2.1 Unfavorable reimbursement scenario
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Growth opportunities in growing economies
           5.2.4 CHALLENGES
                    5.2.4.1 Changing regulatory landscape
                    5.2.4.2 Operational barriers
           5.2.5 COVID-19 IMPACT ANALYSIS
    5.3 PRICING ANALYSIS
           TABLE 2 PRICING ANALYSIS OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS (2021)
    5.4 PATENT ANALYSIS
           5.4.1 POLYMERASE CHAIN REACTION
           5.4.2 IMMUNODIAGNOSTICS
    5.5 VALUE CHAIN ANALYSIS
           FIGURE 19 VALUE CHAIN ANALYSIS OF THE INFECTIOUS DISEASE DIAGNOSTICS MARKET
    5.6 SUPPLY CHAIN ANALYSIS
           FIGURE 20 SUPPLY CHAIN ANALYSIS
    5.7 ECOSYSTEM ANALYSIS
    5.8 PORTER’S FIVE FORCES ANALYSIS
           TABLE 3 INFECTIOUS DISEASE DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.8.1 THREAT FROM NEW ENTRANTS
           5.8.2 THREAT FROM SUBSTITUTES
           5.8.3 BARGAINING POWER OF BUYERS
           5.8.4 BARGAINING POWER OF SUPPLIERS
           5.8.5 COMPETITIVE RIVALRY AMONG EXISTING PLAYERS
    5.9 PESTLE ANALYSIS
    5.10 REGULATORY LANDSCAPE
           5.10.1 NORTH AMERICA
                    5.10.1.1 US
                    5.10.1.2 Canada
           5.10.2 EUROPE
           5.10.3 ASIA PACIFIC
                    5.10.3.1 China
                    5.10.3.2 Japan
                    5.10.3.3 India
           5.10.4 LATIN AMERICA
                    5.10.4.1 Brazil
                    5.10.4.2 Mexico
           5.10.5 MIDDLE EAST
           5.10.6 AFRICA
    5.11 TRADE ANALYSIS
           5.11.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
                    TABLE 4 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2016─2020 (USD MILLION)
                    TABLE 5 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2016─2020 (TONS)
           5.11.2 TRADE ANALYSIS FOR CULTURE MEDIA
                    TABLE 6 IMPORT DATA FOR CULTURE MEDIA, BY COUNTRY, 2016─2020 (USD MILLION)
                    TABLE 7 IMPORT DATA FOR CULTURE MEDIA, BY COUNTRY, 2016─2020 (TONS)
    5.12 TECHNOLOGY ANALYSIS
    5.13 YC–YCC SHIFT
                    FIGURE 21 YC–YCC SHIFT FOR THE INFECTIOUS DISEASE DIAGNOSTICS MARKET

6 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (Page No. - 73)
    6.1 INTRODUCTION
           TABLE 8 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
    6.2 REAGENTS, KITS, AND CONSUMABLES
           6.2.1 REPEAT PURCHASE OF REAGENTS, KITS, AND CONSUMABLES DRIVES THE MARKET GROWTH
                    TABLE 9 INFECTIOUS DISEASE DIAGNOSTICS REAGENTS, KITS, AND CONSUMABLES MARKET, BY REGION, 2019–2026 (USD MILLION)
    6.3 INSTRUMENTS
           6.3.1 INCREASING NEED FOR FASTER & ACCURATE TEST RESULTS TO PROPEL THE MARKET GROWTH
                    TABLE 10 KEY PRODUCTS IN THE INSTRUMENTS MARKET
                    TABLE 11 INFECTIOUS DISEASE DIAGNOSTICS INSTRUMENTS MARKET, BY REGION, 2019–2026 (USD MILLION)
    6.4 SOFTWARE & SERVICES
           6.4.1 NEED TO DELIVER ACCURATE AND TIMELY ANALYSIS OF DIAGNOSTIC TESTS
                    TABLE 12 INFECTIOUS DISEASE DIAGNOSTICS SOFTWARE & SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)

7 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING (Page No. - 79)
    7.1 INTRODUCTION
           TABLE 13 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2019–2026 (USD MILLION)
    7.2 LABORATORY TESTING
           7.2.1 OUTBREAK OF COVID-19 DRIVES DEMAND FOR LAB TESTS
                    TABLE 14 LABORATORY TESTING MARKET, BY REGION, 2019–2026 (USD MILLION)
    7.3 POC TESTING
           7.3.1 THE INCREASING ADOPTION OF POC TECHNOLOGIES DRIVES THE GROWTH OF THIS SEGMENT
                    TABLE 15 POC TESTING MARKET, BY REGION, 2019–2026 (USD MILLION)

8 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY (Page No. - 83)
    8.1 INTRODUCTION
           TABLE 16 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
    8.2 IMMUNODIAGNOSTICS
           8.2.1 RISING PREVALENCE OF INFECTIOUS DISEASES AND DEMAND FOR COVID-19 DIAGNOSTICS DRIVE MARKET GROWTH
                    TABLE 17 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY REGION, 2019–2026 (USD MILLION)
    8.3 POLYMERASE CHAIN REACTION
           8.3.1 THE GROWING USE OF RT-PCR IN COVID-19 TESTS IS A MAJOR GROWTH DRIVER FOR THIS SEGMENT
                    TABLE 18 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR PCR, BY REGION, 2019–2026 (USD MILLION)
    8.4 CLINICAL MICROBIOLOGY
           8.4.1 GROWING ADOPTION BY RESEARCHERS AND ACADEMIA IS EXPECTED TO DRIVE MARKET GROWTH
                    TABLE 19 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY REGION, 2019–2026 (USD MILLION)
    8.5 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
           8.5.1 COST-BENEFITS OF INAAT DRIVE DEMAND FOR THE TECHNOLOGY
                    TABLE 20 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2019–2026 (USD MILLION)
    8.6 DNA SEQUENCING & NGS
           8.6.1 INCREASING FOCUS ON PERSONALIZED MEDICINE IS A GROWTH  DRIVER FOR THIS SEGMENT
                    TABLE 21 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, BY REGION, 2019–2026 (USD MILLION)
    8.7 DNA MICROARRAYS
           8.7.1 GROWING AWARENESS ABOUT ADVANCED TECHNOLOGIES TO DRIVE MARKET GROWTH
                    TABLE 22 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY REGION, 2019–2026 (USD MILLION)
    8.8 OTHER TECHNOLOGIES
           TABLE 23 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2019–2026 (USD MILLION)

9 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE (Page No. - 92)
    9.1 INTRODUCTION
           TABLE 24 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019–2026 (USD MILLION)
    9.2 COVID-19
           9.2.1 HIGH AND GROWING CASE PREVALENCE ENSURES DEMAND FOR COVID-19 DIAGNOSTICS
                    TABLE 25 DISTRIBUTION OF CASES BY COUNTRY
                    TABLE 26 COVID-19 DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 27 COVID-19 DIAGNOSTICS MARKET, BY REGION, 2019–2026 (MILLION TESTS)
                    TABLE 28 COVID-19 DIAGNOSTICS MARKET, BY METHOD, 2019–2026 (USD MILLION)
    9.3 HUMAN IMMUNODEFICIENCY VIRUS
           9.3.1 THE HIGH PREVALENCE OF HIV WILL DRIVE THE MARKET GROWTH FOR THIS SEGMENT
                    TABLE 29 HIV DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 30 HIV DIAGNOSTICS MARKET, BY REGION, 2019–2026 (MILLION TESTS)
    9.4 HOSPITAL-ACQUIRED INFECTIONS
           9.4.1 THE RISING BURDEN OF MRSA INFECTIONS IS A KEY FACTOR DRIVING THE MARKET GROWTH FOR THIS SEGMENT
                    TABLE 31 HAI DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 32 HAI DIAGNOSTICS MARKET, BY REGION, 2019–2026 (MILLION TESTS)
    9.5 HEPATITIS
           9.5.1 THE GLOBAL PREVALENCE OF HEPATITIS IS A KEY FACTOR DRIVING MARKET GROWTH
                    TABLE 33 HEPATITIS DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 34 HEPATITIS DIAGNOSTICS MARKET, BY REGION, 2019–2026 (MILLION TESTS)
                    TABLE 35 HEPATITIS DIAGNOSTICS MARKET, BY METHOD, 2019–2026 (USD MILLION)
    9.6 CHLAMYDIA TRACHOMATIS GENITAL INFECTIONS AND GONORRHEA
           9.6.1 CT/NG INFECTIONS ARE THE MOST COMMON STDS
                    TABLE 36 CT/NG DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 37 CT/NG DIAGNOSTICS MARKET, BY REGION, 2019–2026 (MILLION TESTS)
    9.7 HUMAN PAPILLOMA VIRUS
           9.7.1 TECHNOLOGICAL ADVANCEMENTS SUCH AS RAPID HPV DIAGNOSTICS TO DRIVE THE MARKET GROWTH FOR THIS SEGMENT
                    TABLE 38 HPV DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 39 HPV DIAGNOSTICS MARKET, BY REGION, 2019–2026 (MILLION TESTS)
    9.8 TUBERCULOSIS
           9.8.1 THE INCREASING BURDEN OF TB GLOBALLY TO DRIVE THE MARKET GROWTH OF THIS SEGMENT
                    TABLE 40 TUBERCULOSIS DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 41 TUBERCULOSIS DIAGNOSTICS MARKET, BY REGION, 2019–2026 (MILLION TESTS)
                    TABLE 42 TUBERCULOSIS DIAGNOSTICS MARKET, BY METHOD, 2019–2026 (USD MILLION)
    9.9 INFLUENZA
           9.9.1 RISING FOCUS ON CONTAINING THE SPREAD OF INFLUENZA
                    TABLE 43 INFLUENZA DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 44 INFLUENZA DIAGNOSTICS MARKET, BY REGION, 2019–2026 (MILLION TESTS)
                    TABLE 45 INFLUENZA DIAGNOSTICS MARKET, BY METHOD, 2019–2026 (USD MILLION)
    9.10 OTHER INFECTIOUS DISEASES
           TABLE 46 OTHER INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION)

10 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER (Page No. - 104)
     10.1 INTRODUCTION
               TABLE 47 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
     10.2 DIAGNOSTIC LABORATORIES
             10.2.1 INCREASING OUTSOURCING TO DIAGNOSTIC LABORATORIES FOR REDUCED COSTS DRIVES MARKET GROWTH
                       TABLE 48 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2019–2026 (USD MILLION)
     10.3 HOSPITALS & CLINICS
             10.3.1 HOSPITALS & CLINICS SHOW INCREASING ADOPTION RATE OF INFECTIOUS DISEASE DIAGNOSTIC TOOLS
                       TABLE 49 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2019–2026 (USD MILLION)
     10.4 ACADEMIC RESEARCH INSTITUTES
             10.4.1 FOCUS ON DEVELOPING INNOVATIVE TESTS DRIVES MARKET GROWTH
                       TABLE 50 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2019–2026 (USD MILLION)
     10.5 OTHER END USERS
               TABLE 51 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2019–2026 (USD MILLION)

11 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION (Page No. - 110)
     11.1 INTRODUCTION
               TABLE 52 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION)
     11.2 NORTH AMERICA
               FIGURE 22 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SNAPSHOT
               TABLE 53 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
               TABLE 54 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
               TABLE 55 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
               TABLE 56 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019–2026 (USD MILLION)
               TABLE 57 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.2.1 US
                       11.2.1.1 US dominates the market in North America and globally
                                   TABLE 58 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                                   TABLE 59 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                   TABLE 60 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019–2026 (USD MILLION)
                                   TABLE 61 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.2.2 CANADA
                       11.2.2.1 Focus on affordable tests drives the market growth
                                   TABLE 62 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                                   TABLE 63 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                   TABLE 64 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019–2026 (USD MILLION)
                                   TABLE 65 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
     11.3 EUROPE
               TABLE 66 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
               TABLE 67 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
               TABLE 68 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
               TABLE 69 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019–2026 (USD MILLION)
               TABLE 70 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.3.1 GERMANY
                       11.3.1.1 Germany holds the largest share of the market in Europe
                                   TABLE 71 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                                   TABLE 72 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                   TABLE 73 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019–2026 (USD MILLION)
                                   TABLE 74 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.3.2 ITALY
                       11.3.2.1 Adoption of advanced diagnostic technologies to drive market growth in Italy
                                   TABLE 75 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                                   TABLE 76 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                   TABLE 77 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019–2026 (USD MILLION)
                                   TABLE 78 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.3.3 FRANCE
                       11.3.3.1 Rising R&D expenditure in France
                                   TABLE 79 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                                   TABLE 80 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                   TABLE 81 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019–2026 (USD MILLION)
                                   TABLE 82 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.3.4 SPAIN
                       11.3.4.1 Healthcare infrastructural improvements indicate favorable prospects for market growth
                                   TABLE 83 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                                   TABLE 84 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                   TABLE 85 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019–2026 (USD MILLION)
                                   TABLE 86 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.3.5 UK
                       11.3.5.1 The increasing number of accredited diagnostic laboratories propels market growth in the UK
                                   TABLE 87 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                                   TABLE 88 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                   TABLE 89 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE,  2019–2026 (USD MILLION)
                                   TABLE 90 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.3.6 REST OF EUROPE
                       TABLE 91 ROE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                       TABLE 92 ROE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                       TABLE 93 ROE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019–2026 (USD MILLION)
                       TABLE 94 ROE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
     11.4 ASIA PACIFIC
               FIGURE 23 APAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET SNAPSHOT
               TABLE 95 APAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
               TABLE 96 APAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
               TABLE 97 APAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
               TABLE 98 APAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019–2026 (USD MILLION)
               TABLE 99 APAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.4.1 CHINA
                       11.4.1.1 Growing access to modern healthcare and outbreak of COVID-19
                                   TABLE 100 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                                   TABLE 101 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                   TABLE 102 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019–2026 (USD MILLION)
                                   TABLE 103 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.4.2 JAPAN
                       11.4.2.1 Universal healthcare reimbursement policy to drive market growth in Japan
                                   TABLE 104 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                                   TABLE 105 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                   TABLE 106 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019–2026 (USD MILLION)
                                   TABLE 107 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.4.3 INDIA
                       11.4.3.1 Increasing private & public investments in the country’s healthcare system will drive market growth
                                   TABLE 108 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                                   TABLE 109 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                   TABLE 110 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019–2026 (USD MILLION)
                                   TABLE 111 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.4.4 REST OF ASIA PACIFIC
                       TABLE 112 ROAPAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                       TABLE 113 ROAPAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                       TABLE 114 ROAPAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019–2026 (USD MILLION)
                       TABLE 115 ROAPAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
     11.5 LATIN AMERICA
             11.5.1 RISING DISEASE PREVALENCE AND HEALTHCARE EXPENDITURE HAVE DRAWN FOREIGN PLAYERS TO LATAM MARKETS
                       TABLE 116 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                       TABLE 117 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                       TABLE 118 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019–2026 (USD MILLION)
                       TABLE 119 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
     11.6 MIDDLE EAST & AFRICA
             11.6.1 RISING ACCESS TO ADVANCED TECHNOLOGIES AND GROWING INVESTMENTS WILL SUPPORT MARKET GROWTH
                       TABLE 120 MEA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                       TABLE 121 MEA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                       TABLE 122 MEA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019–2026 (USD MILLION)
                       TABLE 123 MEA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)

12 COMPETITIVE LANDSCAPE (Page No. - 148)
     12.1 OVERVIEW
               FIGURE 24 KEY STRATEGIES IN THE INFECTIOUS DISEASE DIAGNOSTICS MARKET (2018–2021)
     12.2 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
               FIGURE 25 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS IN THE INFECTIOUS DISEASE DIAGNOSTICS MARKET
     12.3 MARKET SHARE ANALYSIS
               FIGURE 26 INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER (2020)
             12.3.1 INFECTIOUS DISEASE DIAGNOSTICS MARKET RANKING, BY DISEASE TYPE
                       12.3.1.1 Hepatitis
                                   TABLE 124 GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY KEY PLAYER, 2020
                       12.3.1.2 HIV
                                   TABLE 125 GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY KEY PLAYER, 2020
                       12.3.1.3 HPV
                                   TABLE 126 GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY KEY PLAYER, 2020
                       12.3.1.4 Influenza
                                   TABLE 127 GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY KEY PLAYER, 2020
                       12.3.1.5 COVID-19
                                   TABLE 128 GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR COVID-19, BY KEY PLAYER, 2020
     12.4 COMPANY EVALUATION QUADRANT
             12.4.1 STARS
             12.4.2 EMERGING LEADERS
             12.4.3 PERVASIVE PLAYERS
             12.4.4 PARTICIPANTS
                       FIGURE 27 INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPANY EVALUATION QUADRANT, 2020
     12.5 COMPANY EVALUATION QUADRANT FOR START-UPS/SMES (2020)
             12.5.1 PROGRESSIVE COMPANIES
             12.5.2 STARTING BLOCKS
             12.5.3 RESPONSIVE COMPANIES
             12.5.4 DYNAMIC COMPANIES
                       FIGURE 28 INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES (2020)
     12.6 PRODUCT AND GEOGRAPHICAL FOOTPRINT ANALYSIS OF TOP PLAYERS
               FIGURE 29 PRODUCT AND GEOGRAPHICAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN THE INFECTIOUS DISEASE DIAGNOSTICS MARKET
     12.7 COMPETITIVE SCENARIO
             12.7.1 MARKET EVALUATION MATRIX, 2018–2020
             12.7.2 INFECTIOUS DISEASE DIAGNOSTICS: PRODUCT LAUNCHES & APPROVALS
                       TABLE 129 KEY PRODUCT LAUNCHES & APPROVALS
             12.7.3 INFECTIOUS DISEASE DIAGNOSTICS: DEALS
                       TABLE 130 KEY DEALS
             12.7.4 INFECTIOUS DISEASE DIAGNOSTICS: OTHER DEVELOPMENTS
                       TABLE 131 OTHER KEY DEVELOPMENTS

13 COMPANY PROFILES (Page No. - 159)
     13.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, right to win)*
             13.1.1 ABBOTT LABORATORIES
                       TABLE 132 ABBOTT LABORATORIES: BUSINESS OVERVIEW
                       FIGURE 30 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020)
             13.1.2 F. HOFFMANN-LA ROCHE
                       TABLE 133 F. HOFFMANN-LA ROCHE: BUSINESS OVERVIEW
                       FIGURE 31 F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT (2020)
             13.1.3 BIOMÉRIEUX SA
                       TABLE 134 BIOMÉRIEUX SA: BUSINESS OVERVIEW
                       FIGURE 32 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2020)
             13.1.4 THERMO FISHER SCIENTIFIC
                       TABLE 135 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
                       FIGURE 33 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2020)
             13.1.5 DANAHER CORPORATION
                       TABLE 136 DANAHER CORPORATION: BUSINESS OVERVIEW
                       FIGURE 34 DANAHER CORPORATION: COMPANY SNAPSHOT (2020)
             13.1.6 QUIDEL CORPORATION
                       TABLE 137 QUIDEL CORPORATION: BUSINESS OVERVIEW
                       FIGURE 35 QUIDEL CORPORATION: COMPANY SNAPSHOT (2020)
             13.1.7 HOLOGIC
                       TABLE 138 HOLOGIC: BUSINESS OVERVIEW
                       FIGURE 36 HOLOGIC: COMPANY SNAPSHOT (2020)
             13.1.8 PERKINELMER
                       TABLE 139 PERKINELMER: BUSINESS OVERVIEW
                       FIGURE 37 PERKINELMER: COMPANY SNAPSHOT (2020)
             13.1.9 BECTON, DICKINSON AND COMPANY
                       TABLE 140 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
                       FIGURE 38 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020)
             13.1.10 SIEMENS HEALTHINEERS AG
                                   TABLE 141 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW
                                   FIGURE 39 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2020)
             13.1.11 DIASORIN S.P.A
                                   TABLE 142 DIASORIN S.P.A: BUSINESS OVERVIEW
                                   FIGURE 40 DIASORIN S.P.A: COMPANY SNAPSHOT (2020)
             13.1.12 BIO-RAD LABORATORIES
                                   TABLE 143 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
                                   FIGURE 41 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2020)
             13.1.13 QIAGEN
                                   TABLE 144 QIAGEN: BUSINESS OVERVIEW
                                   FIGURE 42 QIAGEN N.V.: COMPANY SNAPSHOT (2020)
             13.1.14 GRIFOLS S.A.
                                   TABLE 145 GRIFOLS S.A.: BUSINESS OVERVIEW
                                   FIGURE 43 GRIFOLS S.A.: COMPANY SNAPSHOT (2020)
             13.1.15 ORTHO CLINICAL DIAGNOSTICS
                                   TABLE 146 ORTHO CLINICAL DIAGNOSTICS: BUSINESS OVERVIEW
                                   FIGURE 44 ORTHO CLINICAL DIAGNOSTICS: COMPANY SNAPSHOT (2020)
             13.1.16 SYSMEX CORPORATION
                                   TABLE 147 SYSMEX CORPORATION: BUSINESS OVERVIEW
                                   FIGURE 45 SYSMEX CORPORATION: COMPANY SNAPSHOT (2020)
     13.2 OTHER PLAYERS
             13.2.1 LUMINEX CORPORATION
             13.2.2 MERIDIAN BIOSCIENCE
             13.2.3 TRINITY BIOTECH
             13.2.4 CHEMBIO DIAGNOSTIC SYSTEMS
             13.2.5 ORASURE TECHNOLOGIES
             13.2.6 SEEGENE
             13.2.7 CO-DIAGNOSTICS
             13.2.8 GENETIC SIGNATURES
             13.2.9 EPITOPE DIAGNOSTICS
             13.2.10 TRIVITRON HEALTHCARE
             13.2.11 ELITECHGROUP
             13.2.12 MERIL LIFESCIENCES PVT. LTD.
             13.2.13 INBIOS INTERNATIONAL
             13.2.14 ABACUS DIAGNOSTICA OY

*Details on Business Overview, Products Offered, Recent Developments, SWOT Analysis, right to win might not be captured in case of unlisted companies.

14 APPENDIX (Page No. - 256)
     14.1 INSIGHTS FROM INDUSTRY EXPERTS
     14.2 DISCUSSION GUIDE
     14.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     14.4 AVAILABLE CUSTOMIZATIONS
     14.5 RELATED REPORTS
     14.6 AUTHOR DETAILS


This study involved four major activities in estimating the current size of the infectious disease diagnostics market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate segments and subsegments' market size.

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects.

The following is a breakdown of the primary respondents:

Infectious Disease Diagnostics Market  Size, and Share

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the infectious disease diagnostics market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry have been identified through extensive secondary research
  • The revenues generated by leading players operating in the infectious disease diagnostics market have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Global Infectious Disease Diagnostics Market Size: Top-Down Approach

Infectious Disease Diagnostics Market  Size, and Share

Data Triangulation

After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, segment, and forecast the global infectious disease diagnostics market by product & service, type of testing, technology, disease type, end user, and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies2
  • To track and analyze company developments such as acquisitions, product launches and approvals, expansions, and other developments in the infectious disease diagnostics market.
  • To benchmark players within the market using the proprietary "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Country Information

  • Infectious Disease Diagnostics market size and growth rate estimates for countries in the Rest of Europe, the Rest of Asia Pacific, Latin America, and Middle East & Africa

Company profiles

  • Additional 18 company profiles of players operating in the infectious disease diagnostics market
COVID-19

Get in-depth analysis of the COVID-19 impact on the Infectious Disease Diagnostics Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the Infectious Disease Diagnostics Market

Request For Special Pricing
Report Code
MD 3088
Published ON
May, 2021
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Infectious Disease Diagnostics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2021 MarketsandMarkets Research Private Ltd. All rights reserved
...

Digital Virtual Assistant - MarketsandMarkets

Home